Posters, white papers and other resources
Resources
Publications
With an innovative, super sensitive technology, so-called superRCA analyzes, any remaining cancer cells can be detected after treatment of acute myeloid leukemia (AML). The method is presented in an article in Nature Communication, this is the technology on which Rarity Bioscience is based and the article describes the application in Leukemia.
New article
Improved diagnostic screening and classification of clonal mast cell diseases by ultrasensitive KIT p.D816V detection
This study evaluates a new Flow-SuperRCA® assay for detecting KIT p.D816V mutations in mast cell activation syndromes and mastocytosis. It showcases the assay’s superior sensitivity and specificity over conventional methods, revealing previously undetected clonality and improving diagnostic accuracy.
New article
Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia
This study assesses the prognostic value of persisting IDH1/2 mutations as measurable residual disease (MRD) markers in acute myeloid leukemia. It showcases that persistent IDH2, but not IDH1, mutations after chemotherapy strongly predict relapse risk, highlighting IDH2 as a promising new molecular MRD marker.
New article
Impact of Molecular Evaluations in the Biology, Diagnosis and Prognostication of Patients with Mastocytosis
This review explores the critical role of different molecular diagnostics for detecting KIT D816V mutation in mastocytosis, highlighting their impact on diagnosis, prognosis, and risk stratification. The superRCA ultra-high sensitivity assay has been highlighted in comparison with other molecular techniques for KIT D816V mutation detection.
Researchers from Uppsala University successfully showcased the superRCA assay’s multiplexing ability to study measurable residual disease (MRD) in Colorectal Cancer patients as a suitable tool for non-invasive diagnostic biomarkers from plasma samples.
From Uppsala University and Karolinska Institute: This perspective article compares existing techniques and the benefits and drawbacks of various types of assays for different applications, and their utility for diagnosis and monitoring.
From the author: “Improved methods for molecular analyses are obviously central for medical research. I will describe herein our work developing tools to reveal molecular states in health and disease. I will recount how I got started in this endeavor, and how our early work characterizing genetic variation led onto high-throughput protein measurements and to techniques for imaging the distribution of proteins and their activity states in tissues.”
White Papers
This white paper explores the critical choice of DNA vs RNA as input material for detecting NPM1 mutations in Acute Myeloid Leukemia (AML). Take a deep dive into the performance of DNA and RNA based techniques and learn how DNA-based assays, including superRCA, offer a robust and scalable alternative to RNA-based methods, potentially improving early relapse prediction and treatment decisions.
Posters
Poster presented at the 11th Translational Research Conference: Myeloproliferative Neoplasms in Estoril, Portugal. The data demonstrate a highly sensitive and robust DNA-based JAK2 V617F assay, supporting its suitability for MRD-level analysis. The study included verification and benchmarking using a corresponding WHO 1st International Reference Panel for Genomic JAK2 V617F (NIBSC code: 16/120).
Poster presented at International Symposium ACUTE LEUKEMIAS XIX in Münich. The poster highlights the innovative superRCA mutation assay, which offers unparalleled sensitivity and specificity in detecting tumor-specific mutations, this time using dried blood spots (DBS).
Poster from ICCS 2024 in Seattle, demonstrating superRCA assay for highly sensitive and multiplex detection of mutations in both haematology and solid tumor applications using flow cytometry readout.
In collaboration with Uppsala University.
Poster from ESCCA 2024. The study evaluates the superRCA assay for detecting driver mutations in pediatric AML, showcasing a remarkable mean variation when compared to NGS and an exceptional low detection limit, highlighting its value for monitoring MRD.
In collaboration with St. Anna Children´s Cancer Research Institute, Labdia Labordiagnostik and St. Anna Children’s Hospital.
Poster from ESCCA 2024. The study evaluates the superRCA assay for detecting NPM1 mutations in AML patients and showcases how the superRCA assay offers higher sensitivity and specificity for MRD detection using flow cytometry, compared to RNA-based methods like RT-qPCR.
In collaboration with Sahlgrenska Academy and Sahlgrenska University Hospital.
Poster from ESCCA 2024. The study evaluates the superRCA assay for detecting WT1 mutations in pediatric AML for MRD monitoring. Results show high sensitivity, specificity, and reliable quantification without needing reference samples.
In collaboration with University of Duisburg-Essen.
Rarity Bioscience’s Linus Bosaeus and Feri Shahin attended the NPMF in Stockholm, to present this engaging study. The study explores the utility of a flow-based superRCA assay for detecting circulating tumor DNA (ctDNA) in colorectal cancer (CRC) patients, aiming to establish non-invasive biomarkers for cancer recurrence monitoring.
Presented by CEO Linus Bosaeus during the 13th CNAPS International Conference in Graz. The poster demonstrates how the superRCA assays enable ultra-sensitive, rapid and highly specific detection of rare cancer mutations in colorectal cancer patients, even when DNA variants are present at low frequencies
The study explores the potential of circulating tumor DNA (ctDNA) in plasma samples for patient stratification and treatment monitoring in colorectal cancer cases, and demonstrates how the superRCA technology and a 44-plex panel in 1.8mL plasma achieves unmatched sensitivity in mutation detection.
Presented by Anna Robelius, specialist in Hematology at Uppsala University Hospital, during the ESH AML 2023 conference. The poster demonstrates positive results from a pilot study looking at the utility of using peripheral blood vs. bone marrow for molecular MRD using the ultra-sensitive superRCA assays.
CEO Linus Bosaeus, CTO Lei Chen and Dir. BD Alexander Kele attended the ISMRC (International Symposium on Minimal Residual Cancer) Conference in Hamburg, Germany, 2023, to present a new poster. The poster demonstrates initial data from a pilot study looking at the utility of cfDNA mutation detection in low volumes of blood plasma to monitor treatment and residual disease using the ultra-sensitive superRCA assays.
CEO Linus Bosaeus and co-founder and CTO Dr. Lei Chen presented poster #79 during the AML Conference, to discuss the main topics, such as novel target therapies and markers for Diagnosis and Prognosis. The poster demonstrates positive results from a pilot study looking at the utility of using peripheral blood vs. bone marrow for molecular MRD using the ultra-sensitive superRCA assays.
Poster presentation by Lei Chen,PhD at the European Association for Cancer Research conference on Liquid Biopsy in Bergamo, Italy. The poster focused on the superRCA single tube assay workflow, the assay sensitivity and precision, followed by multiplex example from colorectal patients.
Lei Chen, PhD attended the Nordic Flow Cytometry meeting in Oslo where he presented this poster on the topic of Ultra-sensitive monitoring of leukemia patients using SuperRCA mutation detection assays with Flow Cytometer Readout.
Presentations
Rarity Bioscience’s Linus Bosaeus and Lei Chen were at the CYTO 2024 Conference in Edinburgh, to showcase our ultra-sensitive mutation detection technology superRCA. The presentation displayed the use of standard flow cytometry for nucleic acid detection, introducing the groundbreaking superRCA technology and its precision in detecting genetic mutations at ultra-low levels.
During the ASH Annual Meeting 2023, Linus Bosaeus showcased the superRCA Mutation Assay in a scientific workshop. The presentation details the technology and its ability to attain a sensitivity of 1 in 100,000 on standard flow cytometers. It also demonstrates how superRCA compares to methods like NGS and ddPCR, detecting molecular MRD 10-100 times more sensitively.
Explains the ultra-sensitive superRCA technology, shows data on sensitivity and performance in comparison with current methods, and uses a patient case to show why it matters in MRD. In the presentation you can see results of testing AML patients using FCM, NGS, ddPCR and Rarity Biosciences ultra-sensitive superRCA. The presentation also suggests why Flow-MRD and superRCA molecular-MRD could be a good match in AML patient monitoring.
Certificates
Rarity Bioscience is a ISO 13485 Certified Company. Download the certificate here!
Effective Date: 2023-07-11
Rarity Bioscience is a ISO 13485 Certified Company. Download the certificate here!
Effective Date: 2026-07-11